Apira Science’s iGrow In-Home, Hands-Free Hair Growth System Earns FDA Clearance

Apira Science, Inc. recently earned 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its iGrow® Hair Growth System, which is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V. The iGrow is currently available by prescription only.

More than 35 million men in the U.S. are afflicted with male pattern hair loss, which can begin in the late teen years and progress throughout a lifetime. The iGrow Hair Growth System is the first hands-free, low-level laser therapy (LLLT) hair growth device cleared by the FDA for use at home. Its patented red light technology treats affected areas of the scalp by energizing cells and promoting hair growth.

“Previously, treatments for male pattern hair loss required a trip to a doctor’s office, were cumbersome to use, or carried long-term side effects,” said Nicholas Brox, president and CEO at Apira Science, Inc. “The iGrow Hair Growth System, however, offers consumers a simple, highly effective, and safe approach to growing hair in the comfort and privacy of their own home.

Through this FDA clearance, we’re making available a practical LLLT device that represents a milestone for Apira Science and that is an affordable solution for all men who suffer from androgenetic alopecia.

We’re now working to broaden its use by seeking clearance to offer iGrow over the counter and for use among women.”

Born of years of scientific research and expertise in LLLT, the iGrow Hair Growth System uses low-level red laser and LED light to re-energize cells at the follicle level, achieving an increase in terminal hair counts up to 39 percent after 16 weeks of therapy.

Compared to other LLLT products on the market, iGrow can promote nearly double the increase in hair growth and do so 10 weeks faster.

For more information on the iGrow Hair Growth System, visit www.igrowlaser.com.

Source